According to a recent LinkedIn post from 4BIO Capital, portfolio company Ray Therapeutics, Inc. has reportedly closed an upsized and oversubscribed $125 million Series B financing to advance its optogenetic vision restoration platform. The post notes that this funding follows the U.S. FDA granting RMAT Designation to lead candidate RTx‑015 in retinitis pigmentosa, which is portrayed as a sign of clinical and regulatory momentum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post indicates that the Series B proceeds are expected to support two clinical‑stage programs, RTx‑015 for retinitis pigmentosa and RTx‑021 for macular diseases, including Stargardt disease and geographic atrophy age‑related macular degeneration. For investors in 4BIO Capital, this suggests potential value creation within its ophthalmology and gene therapy portfolio if Ray Therapeutics can convert regulatory momentum into successful late‑stage trials and eventual commercial opportunities.
The post also highlights 4BIO Capital’s role as a founding investor in Ray Therapeutics since 2021 and its continued support of the company. This may imply that 4BIO is increasing or at least maintaining its exposure to optogenetics‑based retinal therapies, potentially strengthening its positioning in high‑risk, high‑reward advanced therapy modalities where successful clinical outcomes could materially enhance portfolio returns.